Actively Recruiting
GCC19CART for Patients With Metastatic Colorectal Cancer
Led by Lyell Immunopharma, Inc. · Updated on 2026-02-27
30
Participants Needed
4
Research Sites
513 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study ICT-GCC19CART-US-001 (CARAPIA-1) is a Phase 1 study evaluating the safety, tolerability, clinical activity, pharmacokinetics and pharmacodynamics of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer.
CONDITIONS
Official Title
GCC19CART for Patients With Metastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults > 18 years old
- Clinical and histopathological diagnosis of metastatic colorectal cancer
- Guanylate Cyclase (GCC) positive disease confirmed by immunohistochemistry of tumor tissue
- Limited liver disease with fewer than 7 lesions and largest lesion less than 3 cm
- No surgical options with curative intent
- Prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy in advanced/metastatic setting
- Received anti-vascular endothelial growth factor (anti-VEGF) therapy if not contraindicated
- For RAS wild-type patients, received anti-epidermal growth factor receptor (anti-EGFR) therapy per guidelines
- Treatment discontinued due to disease progression or intolerance
- At least one extracranial measurable target lesion per RECIST 1.1 criteria
You will not qualify if you...
- Tumor lesions located where GCC19CART therapy may cause organ or structure perforation
- Active infectious diseases or comorbid conditions interfering with safety or data quality
- Active infection requiring systemic therapy or fever over 38.1°C within 7 days prior to enrollment
- Unexplained fever over 38.1°C within 7 days prior to enrollment
- Pregnant or breastfeeding women
- Other protocol-defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010
Actively Recruiting
2
University of California San Francisco Medical Center
San Francisco, California, United States, 94143
Actively Recruiting
3
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045
Actively Recruiting
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215-5418
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here